News Article | May 16, 2017
— Esophageal Cancer - Pipeline Market Review, H1 2017 is a new report added to ReportsnReports.com. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Browse the 85 Tables and 11 Figures, 16 Company Profiles, Spread across 493 Pages Report Available at http://www.reportsnreports.com/reports/992867-esophageal-cancer-pipeline-review-h1-2017.html . Drug Profiles of Esophageal Cancer - 1-BB1, ADCT-502, ADXS-HER2, afatinib dimaleate, AL-3818, ALM-301, apatinib, APR-246, atezolizumab, ATL-101, BGBA-317, binimetinib, brontictuzumab, CBT-501, CDX-1401 many more. Main Companies are Adaptimmune Therapeutics Plc, ADC Therapeutics Sar, Aduro BioTech Inc, Advaxis Inc, Advenchen Laboratories LLC , Almac Discovery Ltd, Amgen Inc , Aprea AB , ArQule Inc , Array BioPharma Inc , Aslan Pharmaceuticals Pte Ltd , ATLAB Pharma SAS , Bayer AG , BeiGene Ltd , Beta Pharma Inc , Boehringer Ingelheim GmbH , Bristol-Myers Squibb Company , CBT Pharmaceuticals Inc , Celgene Corp , Celldex Therapeutics Inc, Cellectar Biosciences Inc, CellSeed Inc , Clovis Oncology Inc , Cyclacel Pharmaceuticals Inc , Eli Lilly and Company , F. Hoffmann-La Roche Ltd , Genmab A/S , GlaxoSmithKline Plc, Glycotope GmbH , Hutchison China MediTech Ltd , Ignyta Inc , Immunocore Ltd, ImmunoFrontier Inc , Immunomedics Inc , Intezyne Technologies Inc , Jiangsu Hengrui Medicine Co Ltd , Johnson & Johnson , Komipharm International Co Ltd , Leap Therapeutics Inc , MaxiVAX SA , Mebiopharm Co Ltd , MedImmune LLC , Merck & Co Inc , Novartis AG , Omeros Corp , Oncolys BioPharma Inc , OncoMed Pharmaceuticals Inc , Ono Pharmaceutical Co Ltd , Puma Biotechnology Inc, Rhizen Pharmaceuticals SA , Shionogi & Co Ltd , Spectrum Pharmaceuticals Inc , Stelic Institute & Co Inc , Supratek Pharma Inc 63, Symphogen A/S 63, Taiho Pharmaceutical Co Ltd 64, Taiwan Liposome Company Ltd 64, Takara Bio Inc 65, Transgene Biotek Ltd 65, VioQuest Pharmaceuticals Inc 66, XuanZhu Pharma Co Ltd. Place Order to This Report at http://www.reportsnreports.com/purchase.aspx?name=992867. Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. Treatment includes chemotherapy, radiation therapy and surgery. The Esophageal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 6, 33, 28, 2, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 5, 2 and 1 molecules, respectively. Esophageal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Scope • The pipeline guide provides a snapshot of the global therapeutic landscape of Esophageal Cancer (Oncology). • The pipeline guide reviews pipeline therapeutics for Esophageal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Esophageal Cancer (Oncology) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Esophageal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Esophageal Cancer (Oncology) About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the For more information, please visit http://www.reportsnreports.com/reports/992867-esophageal-cancer-pipeline-review-h1-2017.html
Kageyama S.,Mie University |
Wada H.,Osaka University |
Muro K.,Aichi Cancer Center Hospital |
Niwa Y.,Aichi Cancer Center Hospital |
And 15 more authors.
Journal of Translational Medicine | Year: 2013
Background: Cholesteryl pullulan (CHP) is a novel antigen delivery system for cancer vaccines. This study evaluated the safety, immune responses and clinical outcomes of patients who received the CHP-NY-ESO-1 complex vaccine, Drug code: IMF-001.Methods: Patients with advanced/metastatic esophageal cancer were enrolled and subcutaneously vaccinated with either 100 μg or 200 μg of NY-ESO-1 protein complexed with CHP. The primary endpoints were safety and humoral immune responses, and the secondary endpoint was clinical efficacy.Results: A total of 25 patients were enrolled. Thirteen and twelve patients were repeatedly vaccinated with 100 μg or 200 μg of CHP-NY-ESO-1 with a median of 8 or 9.5 doses, respectively. No serious adverse events related to the vaccine were observed. Three out of 13 patients in the 100-μg cohort and 7 out of 12 patients in the 200-μg cohort were positive for anti-NY-ESO-1 antibodies at baseline. In the 100-μg cohort, an antibody response was observed in 5 out of 10 pre-antibody-negatives patients, and the antibody levels were augmented in 2 pre-antibody-positive patients after vaccination. In the 200-μg cohort, all 5 pre-antibody-negative patients became seropositive, and the antibody level was amplified in all 7 pre-antibody-positive patients. No tumor shrinkage was observed. The patients who received 200 μg of CHP-NY-ESO-1 survived longer than patients receiving 100 μg of CHP-NY-ESO-1, even those who exhibited unresponsiveness to previous therapies or had higher tumor burdens.Conclusions: The safety and immunogenicity of CHP-NY-ESO-1 vaccine were confirmed. The 200 μg dose more efficiently induced immune responses and suggested better survival benefits. (Clinical trial registration number NCT01003808). © 2013 Kageyama et al.; licensee BioMed Central Ltd.
Muraoka D.,Mie University |
Muraoka D.,Immunofrontier Inc. |
Nishikawa H.,Mie University |
Nishikawa H.,Osaka University |
And 10 more authors.
Vaccine | Year: 2013
Many patients develop tumor antigen-specific T cell responses detectable in peripheral blood mononuclear cells (PBMCs) following cancer vaccine. However, measurable tumor regression is observed in a limited number of patients receiving cancer vaccines. There is a need to re-evaluate systemically the immune responses induced by cancer vaccines. Here, we established animal models targeting two human cancer/testis antigens, NY-ESO-1 and MAGE-A4. Cytotoxic T lymphocyte (CTL) epitopes of these antigens were investigated by immunizing BALB/c mice with plasmids encoding the entire sequences of NY-ESO-1 or MAGE-A4. CD8+ T cells specific for NY-ESO-1 or MAGE-A4 were able to be detected by ELISPOT assays using antigen presenting cells pulsed with overlapping peptides covering the whole protein, indicating the high immunogenicity of these antigens in mice. Truncation of these peptides revealed that NY-ESO-1-specific CD8+ T cells recognized Dd-restricted 8mer peptides, NY-ESO-181-88. MAGE-A4-specific CD8+ T cells recognized Dd-restricted 9mer peptides, MAGE-A4265-273. MHC/peptide tetramers allowed us to analyze the kinetics and distribution of the antigen-specific immune responses, and we found that stronger antigen-specific CD8+ T cell responses were required for more effective anti-tumor activity. Taken together, these animal models are valuable for evaluation of immune responses and optimization of the efficacy of cancer vaccines. © 2013 Elsevier Ltd.